Can MRI and nerve tests catch a rare disease before symptoms start?

NCT ID NCT03588468

Completed Knowledge-focused Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at whether advanced MRI scans and a nerve test called MUNIX can detect the earliest signs of nerve damage in people who carry a gene mutation for familial amyloid neuropathy. Researchers studied 60 adults with the TTR mutation, comparing those with and without symptoms. The goal was to see if these tools could help doctors know exactly when to start treatment, avoiding both unnecessary side effects and delayed care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better tools for detecting the earliest signs of disease in people with a genetic risk, allowing for timely treatment decisions.
What could go wrong: This is a small, early exploratory study, not a treatment trial. The new tests may not prove sensitive or specific enough to change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOID NEUROPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies familial amyloid neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOID NEUROPATHIES TRANSTHYRETIN AMYLOIDOSIS

Contacts and locations

Show contact details

Locations

Assistance Publique Des Hopitaux de Marseille

Marseille, PACA, 13354, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.